Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1984 May 12;288(6428):1411–1416. doi: 10.1136/bmj.288.6428.1411

Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukaemia in adults.

PMCID: PMC1441033  PMID: 6326927

Abstract

During March 1980 to February 1982, 73 out of 80 patients in renal failure admitted to the fourth MRC myelomatosis trial were managed by a planned policy of high fluid intake (greater than or equal to 3 1/24 h) in addition to receiving one of the two chemotherapeutic regimens being tested in the main trial. Patients were also randomised to receive either sodium bicarbonate to render their urine neutral or no supplement. Follow up continued till death or to April 1983. Of 49 patients who survived more than 100 days, 39 achieved reversal of their renal failure (18 complete, 21 partial). Recovery of renal function, as assessed by a fall in the serum creatinine concentration, was achieved even when light chain proteinuria persisted. Partial recovery of renal function was associated with prolonged useful life in several patients. In only 14 of the 80 patients studied was death directly attributable to renal failure. Survival of patients in the study was appreciably better than in equivalent groups of patients in other MRC trials in which less stringent policies of fluid intake were used. Patients randomised to receive alkali fared marginally better than the others, but the difference was not significant. These results show that in many cases patients with myelomatosis who develop renal failure may have this complication reversed by taking a high fluid intake. Furthermore, though light chain is an essential component of renal disease in these patients, other factors are also important and are accessible to treatment.

Full text

PDF
1412

Images in this article

1416Above
on p.1416
1416Below
on p.1416

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexanian R., Balcerzak S., Bonnet J. D., Gehan E. A., Haut A., Hewlett J. S., Monto R. W. Prognostic factors in multiple myeloma. Cancer. 1975 Oct;36(4):1192–1201. doi: 10.1002/1097-0142(197510)36:4<1192::aid-cncr2820360403>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  2. Bernstein S. P., Humes H. D. Reversible renal insufficiency in multiple myeloma. Arch Intern Med. 1982 Nov;142(12):2083–2086. [PubMed] [Google Scholar]
  3. Bryan C. W., McIntire K. R. Effect of sustained diuresis on the renal lesions of mice with Bence Jones protein-producing tumors. J Lab Clin Med. 1974 Mar;83(3):409–416. [PubMed] [Google Scholar]
  4. Carbone P. P., Kellerhouse L. E., Gehan E. A. Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med. 1967 Jun;42(6):937–948. doi: 10.1016/0002-9343(67)90074-5. [DOI] [PubMed] [Google Scholar]
  5. Clyne D. H., Kant K. S., Pesce A. J., Pollak V. E. Nephrotoxicity of low molecular weight serum proteins: physicochemical interactions between myoglobin, hemoglobin, bence-jones proteins and tamm-horsfall mucoprotein. Curr Probl Clin Biochem. 1979;(9):299–308. [PubMed] [Google Scholar]
  6. Clyne D. H., Pollak V. E. Renal handling and pathophysiology of Bence Jones proteins. Contrib Nephrol. 1981;24:78–87. doi: 10.1159/000395232. [DOI] [PubMed] [Google Scholar]
  7. Cosio F. G., Pence T. V., Shapiro F. L., Kjellstrand C. M. Severe renal failure in multiple myeloma. Clin Nephrol. 1981 Apr;15(4):206–210. [PubMed] [Google Scholar]
  8. DeFronzo R. A., Cooke C. R., Wright J. R., Humphrey R. L. Renal function in patients with multiple myeloma. Medicine (Baltimore) 1978 Mar;57(2):151–166. doi: 10.1097/00005792-197803000-00003. [DOI] [PubMed] [Google Scholar]
  9. KAY H. E., LEDLIE E. M., SBRESNI R. C. Treatment of multiple myelomatosis with particular reference to radioactive iodine. Report of five cases. Br J Radiol. 1959 Dec;32:791–797. doi: 10.1259/0007-1285-32-384-791. [DOI] [PubMed] [Google Scholar]
  10. Kyle R. A. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975 Jan;50(1):29–40. [PubMed] [Google Scholar]
  11. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  12. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  13. Myers B. D., Carrie B. J., Yee R. R., Hilberman M., Michaels A. S. Pathophysiology of hemodynamically mediated acute renal failure in man. Kidney Int. 1980 Oct;18(4):495–504. doi: 10.1038/ki.1980.163. [DOI] [PubMed] [Google Scholar]
  14. Preud'Homme J. L., Morel-Maroger L., Brouet J. C., Mihaesco E., Mery J. P., Seligmann M. Synthesis of abnormal heavy and light chains in multiple myeloma with visceral deposition of monoclonal immunoglobulin. Clin Exp Immunol. 1980 Dec;42(3):545–553. [PMC free article] [PubMed] [Google Scholar]
  15. Schubert G. E. Die Plasmocytomniere. I. Häufigkeit pathologisch-anatomischer Veränderungen. Klin Wochenschr. 1974 Aug 15;52(16):763–770. doi: 10.1007/BF01468736. [DOI] [PubMed] [Google Scholar]
  16. Schubert G. E. Die Plasmocytomniere. II. Vergleich von Struktur und Funktion unter besonderer Berücksichtigung des akuten Nierenversagens. Klin Wochenschr. 1974 Aug 15;52(16):771–780. doi: 10.1007/BF01468737. [DOI] [PubMed] [Google Scholar]
  17. Schubert G. E., Veigel J., Lennert K. Structure and function of the kidney in multiple myeloma. Virchows Arch A Pathol Pathol Anat. 1972;355(2):135–157. doi: 10.1007/BF00556315. [DOI] [PubMed] [Google Scholar]
  18. Smith J. F., Van Hegan R. I., Esnouf M. P., Ross B. D. Characteristics of renal handling of human immunoglobulin light chain by the perfused rat kidney. Clin Sci (Lond) 1979 Jul;57(1):113–120. doi: 10.1042/cs0570113. [DOI] [PubMed] [Google Scholar]
  19. Solomon A. Bence Jones proteins: malignant or benign? N Engl J Med. 1982 Mar 11;306(10):605–607. doi: 10.1056/NEJM198203113061010. [DOI] [PubMed] [Google Scholar]
  20. Verroust P., Morel-Maroger L., Preud'Homme J. L. Renal lesions in dysproteinemias. Springer Semin Immunopathol. 1982;5(3):333–356. doi: 10.1007/BF01892092. [DOI] [PubMed] [Google Scholar]
  21. Vélez-García E., Maldonado N. Long-term follow-up and therapy in multiple myeloma. Cancer. 1971 Jan;27(1):44–50. doi: 10.1002/1097-0142(197101)27:1<44::aid-cncr2820270108>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  22. Weiss J. H., Williams R. H., Galla J. H., Gottschall J. L., Rees E. D., Bhathena D., Luke R. G. Pathophysiology of acute Bence-Jones protein nephrotoxicity in the rat. Kidney Int. 1981 Aug;20(2):198–210. doi: 10.1038/ki.1981.122. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES